Heart Failure Drugs Market By Drug Type and Distribution Channel - Global Industry Analysis And Forecast To 2025

Published On : November 2018 Pages : 150 Category: Pharmaceuticals Report Code : HC111709

Heart Failure Drugs Market By Drug Type (Beta Blockers, ARBs, ACE Inhibitors and Other Drug Types) and Distribution Channel (Hospitals, Online Pharmacies and Retail Pharmacies) - Global Industry Analysis And Forecast To 2025

Industry Outlook

Heart Failure also referred to as congestive heart failure, is seen when the ability of heart to pump blood is limited. This condition occurs due to narrowed arteries or high BP, which in turn weakens the heart. Symptoms of Heart Failure can be improved with treatment and help to live longer. Heart Failure can be reduced by minimizing intake of sodium in diet, stress & weight management and exercising. Heart Failure Drugs use is growing due to increase in the number of cases of congestive heart failure, approval of number of drugs by the FDA, rise in the aged population across the globe, increased knowledge amongst the people about the treatment of congestive heart failure, etc. Therefore, the Heart Failure Drugs Market is anticipated to expand and has tremendous scope during the forecast period. The global Heart Failure Drugs Market anticipated to flourish in the future by growing at a significantly higher CAGR.

Market Segmentation

The global Heart Failure Drugs Market is based on segment, by Drug Type the market is segmented into Beta Blockers, ARBs, ACE Inhibitors and Other Drug Types, and by Distribution Channel the market is segmented into Hospitals, Online Pharmacies and Retail Pharmacies.

  • Heart Failure Drugs Market, By Drug Type
  • Beta Blockers
  • ARBs
  • ACE Inhibitors
  • Other Drug Types
  • Heart Failure Drugs Market, By Distribution Channel
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies

Regional Insights

On a global front, the Heart Failure Drugs Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA). North American region is leading the Heart Failure Drugs Market owing to number of acquisitions & mergers and also introduction of new products.

Heart Failure Drugs Market, By Region

    • North America
  • U.S.
  • Canada
  • Mexico
    • Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
    • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Southeast Asia
  • Rest of Asia-Pacific
    • South America
  • Brazil
  • Argentina
  • Columbia
  • Rest of South America
    • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Nigeria
  • South Africa
  • Rest of MEA

Competitive Analysis

The leading players in the market are Teva Pharmaceutical Industries Ltd., Bayer AG, Pfizer Inc., Amgen Inc., Glaxo Smith Kline, Novartis AG, Gilead Sciences Inc. and Astra Zeneca Plc.. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.

  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Pfizer Inc.
  • Amgen Inc.
  • Glaxo Smith Kline
  • Novartis AG
  • Gilead Sciences Inc.
  • Astra Zeneca Plc.

Some of the key questions answered by the report are:          

  • What was the market size in 2014 and forecast from 2015 to 2025?
  • What will be the industry market growth from 2015 to 2025?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

o   Heart Failure Drugs Market, By Drug Type, Estimates and Forecast, 2014-2025 ($Million)

o   ACE inhibitors

o   ARBs

o   Beta blockers

o   Other Drug Types

o   Heart Failure Drugs Market, By Distribution Channel, Estimates and Forecast, 2014-2025 ($Million)

o   Hospitals

o   Online Pharmacies

o   Retail Pharmacies

o   Heart Failure Drugs Market, By Region, Estimates and Forecast, 2014-2025 ($Million)

o   North America

§  North America Heart Failure Drugs Market, By Country

o   U.S. Heart Failure Drugs Market

o   Canada Heart Failure Drugs Market

o   Mexico Heart Failure Drugs Market

o   Europe

§  Europe Heart Failure Drugs Market, By Country

o   Germany Heart Failure Drugs Market

o   UK Heart Failure Drugs Market

o   France Heart Failure Drugs Market

o   Russia Heart Failure Drugs Market

o   Italy Heart Failure Drugs Market

o   Rest of Europe Heart Failure Drugs Market

o   Asia-Pacific

§  Asia-Pacific Heart Failure Drugs Market, By Country

o   China Heart Failure Drugs Market

o   Japan Heart Failure Drugs Market

o   South Korea  Heart Failure Drugs Market

o   India Heart Failure Drugs Market

o   Southeast Asia Heart Failure Drugs Market

o   Rest of Asia-Pacific Heart Failure Drugs Market

o   South America

§  South America Heart Failure Drugs Market, By Country

o   Brazil Heart Failure Drugs Market

o   Argentina Heart Failure Drugs Market

o   Columbia Heart Failure Drugs Market

o   Rest of South America Heart Failure Drugs Market

o   Middle East and Africa

§  Middle East and Africa Heart Failure Drugs Market, By Country

o   Saudi Arabia Heart Failure Drugs Market

o   UAE Heart Failure Drugs Market

o   Egypt Heart Failure Drugs Market

o   Nigeria Heart Failure Drugs Market

o   South Africa Heart Failure Drugs Market

o   Rest of MEA Heart Failure Drugs Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2014-2025)

4.1.2.  Canada Market Status and Outlook (2014-2025)

4.1.3.  Mexico Market Status and Outlook (2014-2025)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2014-2025)

4.2.2.  France Market Status and Outlook (2014-2025)

4.2.3.  UK Market Status and Outlook (2014-2025)

4.2.4.  Russia Market Status and Outlook (2014-2025)

4.2.5.  Italy Market Status and Outlook (2014-2025)

4.2.6.  Rest of Europe Market Status and Outlook (2014-2025)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2014-2025)

4.3.2.  Japan Market Status and Outlook (2014-2025)

4.3.3.  Korea Market Status and Outlook (2014-2025)

4.3.4.  India Market Status and Outlook (2014-2025)

4.3.5.  Southeast Asia Market Status and Outlook (2014-2025)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2014-2025)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2014-2025)

4.4.2.  Argentina Market Status and Outlook (2014-2025)

4.4.3.  Columbia Market Status and Outlook (2014-2025)

4.4.4.  Rest of South America Market Status and Outlook (2014-2025)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2014-2025)

4.5.2.  United Arab Emirates Market Status and Outlook (2014-2025)

4.5.3.  Egypt Market Status and Outlook (2014-2025)

4.5.4.  Nigeria Market Status and Outlook (2014-2025)

4.5.5.  South Africa Market Status and Outlook (2014-2025)

4.5.6.  Turkey Market Status and Outlook (2014-2025)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2014-2025)

5.       Heart Failure Drugs Market, By Drug Type

5.1.     Introduction

5.2.     Global Heart Failure Drugs Revenue and Market Share by Drug Type (2014-2018)

5.2.1.  Global Heart Failure Drugs Revenue and Revenue Share by Drug Type (2014-2018)

5.3.     Beta Blockers

5.3.1.  Global Beta Blockers Revenue and Growth Rate (2014-2018)

5.4.     ARBs

5.4.1.  Global ARBs Revenue and Growth Rate (2014-2018)

5.5.     ACE Inhibitors

5.5.1.  Global ACE Inhibitors Revenue and Growth Rate (2014-2018)

5.6.     Other Drug Types

5.6.1.  Global Other Drug Types Revenue and Growth Rate (2014-2018)

6.       Heart Failure Drugs Market, By Distribution Channel

6.1.     Introduction

6.2.     Global Heart Failure Drugs Revenue and Market Share by Distribution Channel (2014-2018)

6.2.1.  Global Heart Failure Drugs Revenue and Revenue Share by Distribution Channel (2014-2018)

6.3.     Hospitals

6.3.1.  Global Hospitals Revenue and Growth Rate (2014-2018)

6.4.     Online Pharmacies

6.4.1.  Global Online Pharmacies Revenue and Growth Rate (2014-2018)

6.5.     Retail Pharmacies

6.5.1.  Global Retail Pharmacies Revenue and Growth Rate (2014-2018)

7.       Heart Failure Drugs Market, By Region

7.1.     Introduction

7.2.     Global Heart Failure Drugs Revenue and Market Share by Regions

7.2.1.  Global Heart Failure Drugs Revenue by Regions (2014-2018)

7.3.     North America Heart Failure Drugs by Countries

7.3.1.  North America Heart Failure Drugs Revenue and Growth Rate (2014-2018)

7.3.2.  North America Heart Failure Drugs Revenue (Million USD) by Countries (2014-2018)

7.3.3.  United States

7.3.3.1.  United States Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.3.4.  Canada

7.3.4.1.  Canada Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.3.5.  Mexico

7.3.5.1.  Mexico Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.4.     Europe Heart Failure Drugs by Countries

7.4.1.  Europe Heart Failure Drugs Revenue and Growth Rate (2014-2018)

7.4.2.  Europe Heart Failure Drugs Revenue (Million USD) by Countries (2014-2018)

7.4.3.  Germany

7.4.3.1.  Germany Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.4.4.  France

7.4.4.1.  France Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.4.5.  UK

7.4.5.1.  UK Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.4.6.  Russia

7.4.6.1.  Russia Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.4.7.  Italy

7.4.7.1.  Italy Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.4.8.  Rest of Europe

7.4.8.1.  Rest of Europe Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.5.     Asia-Pacific Heart Failure Drugs by Countries

7.5.1.  Asia-Pacific Heart Failure Drugs Revenue and Growth Rate (2014-2018)

7.5.2.  Asia-Pacific Heart Failure Drugs Revenue (Million USD) by Countries (2014-2018)

7.5.3.  China

7.5.3.1.  China Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.5.4.  Japan

7.5.4.1.  Japan Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.5.5.  Korea

7.5.5.1.  Korea Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.5.6.  India

7.5.6.1.  India Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.5.7.  Southeast Asia

7.5.7.1.  Southeast Asia Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.5.8.  Rest of Asia-Pacific

7.5.8.1.  Rest of Asia-Pacific Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.6.     South America Heart Failure Drugs by Countries

7.6.1.  South America Heart Failure Drugs Revenue and Growth Rate (2014-2018)

7.6.2.  South America Heart Failure Drugs Revenue (Million USD) by Countries (2014-2018)

7.6.3.  Brazil

7.6.3.1.  Brazil Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.6.4.  Argentina

7.6.4.1.  Argentina Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.6.5.  Columbia

7.6.5.1.  Columbia Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.6.6.  Rest of South America

7.6.6.1.  Rest of South America Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.     Middle East and Africa Heart Failure Drugs by Countries

7.7.1.  Middle East and Africa Heart Failure Drugs Revenue and Growth Rate (2014-2018)

7.7.2.  Middle East and Africa Heart Failure Drugs Revenue (Million USD) by Countries (2014-2018)

7.7.3.  Saudi Arabia

7.7.3.1.  Saudi Arabia Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.4.  United Arab Emirates

7.7.4.1.  United Arab Emirates Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.5.  Egypt

7.7.5.1.  Egypt Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.6.  Nigeria

7.7.6.1.  Nigeria Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.7.  South Africa

7.7.7.1.  South Africa Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.8.  Turkey

7.7.8.1.  Turkey Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.9.  Rest of Middle East and Africa

7.7.9.1.  Rest of Middle East and Africa Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)

8.       Company Profiles

8.1.     Teva Pharmaceutical Industries Ltd.

8.1.1.  Business Overview

8.1.2.   Service Portfolio

8.1.3.  Strategic Developments

8.1.4.   Revenue and Market Share

8.2.     Bayer AG

8.2.1.  Business Overview

8.2.2.   Service Portfolio

8.2.3.  Strategic Developments

8.2.4.   Revenue and Market Share

8.3.     Pfizer Inc.

8.3.1.  Business Overview

8.3.2.   Service Portfolio

8.3.3.  Strategic Developments

8.3.4.   Revenue and Market Share

8.4.     Amgen Inc.

8.4.1.  Business Overview

8.4.2.   Service Portfolio

8.4.3.  Strategic Developments

8.4.4.   Revenue and Market Share

8.5.     Glaxo Smith Kline

8.5.1.  Business Overview

8.5.2.   Service Portfolio

8.5.3.  Strategic Developments

8.5.4.   Revenue and Market Share

8.6.     Novartis AG

8.6.1.  Business Overview

8.6.2.   Service Portfolio

8.6.3.  Strategic Developments

8.6.4.   Revenue and Market Share

8.7.     Gilead Sciences Inc.

8.7.1.  Business Overview

8.7.2.   Service Portfolio

8.7.3.  Strategic Developments

8.7.4.   Revenue and Market Share

8.8.     Astra Zeneca Plc.

8.8.1.  Business Overview

8.8.2.   Service Portfolio

8.8.3.  Strategic Developments

8.8.4.   Revenue and Market Share

9.       Global Heart Failure Drugs Market Competition, by Manufacturer

9.1.     Global Heart Failure Drugs Revenue and Market Share by Manufacturer (2016-2017)

9.2.     Global Heart Failure Drugs Price By Region (2016-2017)

9.3.     Top 5 Heart Failure Drugs Manufacturer Market Share

9.4.     Market Competition Trend

10.    Heart Failure Drugs Market Forecast (2018-2025)

10.1. Global Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2018-2025)

10.2. Heart Failure Drugs Market Forecast by Regions (2018-2025)

10.2.1.      North America Heart Failure Drugs Market Forecast (2018-2025)

10.2.1.1. United States Heart Failure Drugs Market Forecast (2018-2025)

10.2.1.2. Canada Heart Failure Drugs Market Forecast (2018-2025)

10.2.1.3. Mexico Heart Failure Drugs Market Forecast (2018-2025)

10.2.2.      Europe Heart Failure Drugs Market Forecast (2018-2025)

10.2.2.1. Germany Heart Failure Drugs Market Forecast (2018-2025)

10.2.2.2. France Heart Failure Drugs Market Forecast (2018-2025)

10.2.2.3. UK Heart Failure Drugs Market Forecast (2018-2025)

10.2.2.4. Russia Heart Failure Drugs Market Forecast (2018-2025)

10.2.2.5. Italy Heart Failure Drugs Market Forecast (2018-2025)

10.2.2.6. Rest of Europe Heart Failure Drugs Market Forecast (2018-2025)

10.2.3.      Asia-Pacific Heart Failure Drugs Market Forecast (2018-2025)

10.2.3.1. China Heart Failure Drugs Market Forecast (2018-2025)

10.2.3.2. Japan Heart Failure Drugs Market Forecast (2018-2025)

10.2.3.3. Korea Heart Failure Drugs Market Forecast (2018-2025)

10.2.3.4. India Heart Failure Drugs Market Forecast (2018-2025)

10.2.3.5. Southeast Asia Heart Failure Drugs Market Forecast (2018-2025)

10.2.3.6. Rest of Asia-Pacific Heart Failure Drugs Market Forecast (2018-2025)

10.2.4.      South America Heart Failure Drugs Market Forecast (2018-2025)

10.2.4.1. Brazil Heart Failure Drugs Market Forecast (2018-2025)

10.2.4.2. Argentina Heart Failure Drugs Market Forecast (2018-2025)

10.2.4.3. Columbia Heart Failure Drugs Market Forecast (2018-2025)

10.2.4.4. Rest of South America Heart Failure Drugs Market Forecast (2018-2025)

10.2.5.      Middle East and Africa Heart Failure Drugs Market Forecast (2018-2025)

10.2.5.1. Saudi Arabia Heart Failure Drugs Market Forecast (2018-2025)

10.2.5.2. United Arab Emirates Heart Failure Drugs Market Forecast (2018-2025)

10.2.5.3. Egypt Heart Failure Drugs Market Forecast (2018-2025)

10.2.5.4. Nigeria Heart Failure Drugs Market Forecast (2018-2025)

10.2.5.5. South Africa Heart Failure Drugs Market Forecast (2018-2025)

10.2.5.6. Turkey Heart Failure Drugs Market Forecast (2018-2025)

10.2.5.7. Rest of Middle East and Africa Heart Failure Drugs Market Forecast (2018-2025)

10.3. Heart Failure Drugs Market Forecast by Drug Type (2018-2025)

10.3.1.      Heart Failure Drugs Forecast by Drug Type (2018-2025)

10.3.2.      Heart Failure Drugs Market Share Forecast by Drug Type (2018-2025)

10.4. Heart Failure Drugs Market Forecast by Distribution Channel (2018-2025)

10.4.1.      Heart Failure Drugs Forecast by Distribution Channel (2018-2025)

10.4.2.      Heart Failure Drugs Market Share Forecast by Distribution Channel (2018-2025)


List of Tables

List of Tables and Figures:

Figure United States Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Canada Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Mexico Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Germany Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure France Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure UK Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Russia Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Italy Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Rest of Europe Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure China Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Japan Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Korea Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure India Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Southeast Asia Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Rest of Asia-Pacific Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Brazil Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Argentina Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Columbia Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Rest of South America Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Saudi Arabia Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure United Arab Emirates Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Egypt Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Nigeria Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure South Africa Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Turkey Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Figure Rest of Middle East and Africa Heart Failure Drugs Revenue (Million USD) and Growth Rate (2014-2025)
Table Global Heart Failure Drugs Revenue and Revenue Share by Drug Type (2014-2018)
Figure Global Beta Blockers Revenue and Growth Rate (2014-2018)
Figure Global ARBs Revenue and Growth Rate (2014-2018)
Figure Global ACE Inhibitors Revenue and Growth Rate (2014-2018)
Figure Global Other Drug Types Revenue and Growth Rate (2014-2018)
Table Global Heart Failure Drugs Revenue and Revenue Share by Distribution Channel (2014-2018)
Figure Global Hospitals Revenue and Growth Rate (2014-2018)
Figure Global Online Pharmacies Revenue and Growth Rate (2014-2018)
Figure Global Retail Pharmacies Revenue and Growth Rate (2014-2018)
Table Global Heart Failure Drugs Revenue by Regions (2014-2018)
Figure North America Heart Failure Drugs Growth Rate (2014-2018)
Figure North America Heart Failure Drugs Revenue and Growth Rate (2014-2018)
Figure North America Heart Failure Drugs by Countries (2014-2018)
Figure North America Heart Failure Drugs Revenue (Million USD) by Countries (2014-2018)
Figure United States Heart Failure Drugs Growth Rate (2014-2018)
Figure United States Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Canada Heart Failure Drugs Growth Rate (2014-2018)
Figure Canada Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Mexico Heart Failure Drugs Growth Rate (2014-2018)
Figure Mexico Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Europe Heart Failure Drugs Growth Rate (2014-2018)
Figure Europe Heart Failure Drugs Revenue and Growth Rate (2014-2018)
Figure Europe Heart Failure Drugs by Countries (2014-2018)
Figure Europe Heart Failure Drugs Revenue (Million USD) by Countries (2014-2018)
Figure Germany Heart Failure Drugs Growth Rate (2014-2018)
Figure Germany Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure France Heart Failure Drugs Growth Rate (2014-2018)
Figure France Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure UK Heart Failure Drugs Growth Rate (2014-2018)
Figure UK Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Russia Heart Failure Drugs Growth Rate (2014-2018)
Figure Russia Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Italy Heart Failure Drugs Growth Rate (2014-2018)
Figure Italy Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Rest of Europe Heart Failure Drugs Growth Rate (2014-2018)
Figure Rest of Europe Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Asia-Pacific Heart Failure Drugs Growth Rate (2014-2018)
Figure Asia-Pacific Heart Failure Drugs Revenue and Growth Rate (2014-2018)
Figure Asia-Pacific Heart Failure Drugs by Countries (2014-2018)
Figure Asia-Pacific Heart Failure Drugs Revenue (Million USD) by Countries (2014-2018)
Figure China Heart Failure Drugs Growth Rate (2014-2018)
Figure China Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Japan Heart Failure Drugs Growth Rate (2014-2018)
Figure Japan Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Korea Heart Failure Drugs Growth Rate (2014-2018)
Figure Korea Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure India Heart Failure Drugs Growth Rate (2014-2018)
Figure India Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Southeast Asia Heart Failure Drugs Growth Rate (2014-2018)
Figure Southeast Asia Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Rest of Asia-Pacific Heart Failure Drugs Growth Rate (2014-2018)
Figure Rest of Asia-Pacific Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure South America Heart Failure Drugs Growth Rate (2014-2018)
Figure South America Heart Failure Drugs Revenue and Growth Rate (2014-2018)
Figure South America Heart Failure Drugs by Countries (2014-2018)
Figure South America Heart Failure Drugs Revenue (Million USD) by Countries (2014-2018)
Figure Brazil Heart Failure Drugs Growth Rate (2014-2018)
Figure Brazil Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Argentina Heart Failure Drugs Growth Rate (2014-2018)
Figure Argentina Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Columbia Heart Failure Drugs Growth Rate (2014-2018)
Figure Columbia Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Rest of South America Heart Failure Drugs Growth Rate (2014-2018)
Figure Rest of South America Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Middle East and Africa Heart Failure Drugs Growth Rate (2014-2018)
Figure Middle East and Africa Heart Failure Drugs Revenue and Growth Rate (2014-2018)
Figure Middle East and Africa Heart Failure Drugs by Countries (2014-2018)
Figure Middle East and Africa Heart Failure Drugs Revenue (Million USD) by Countries (2014-2018)
Figure Saudi Arabia Heart Failure Drugs Growth Rate (2014-2018)
Figure Saudi Arabia Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure United Arab Emirates Heart Failure Drugs Growth Rate (2014-2018)
Figure United Arab Emirates Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Egypt Heart Failure Drugs Growth Rate (2014-2018)
Figure Egypt Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Nigeria Heart Failure Drugs Growth Rate (2014-2018)
Figure Nigeria Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure South Africa Heart Failure Drugs Growth Rate (2014-2018)
Figure South Africa Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Turkey Heart Failure Drugs Growth Rate (2014-2018)
Figure Turkey Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Rest of Middle East and Africa Heart Failure Drugs Growth Rate (2014-2018)
Figure Rest of Middle East and Africa Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2014-2018)
Table Teva Pharmaceutical Industries Ltd. Heart Failure Drugs Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Bayer AG Heart Failure Drugs Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Pfizer Inc. Heart Failure Drugs Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Amgen Inc. Heart Failure Drugs Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Glaxo Smith Kline Heart Failure Drugs Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Novartis AG Heart Failure Drugs Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Gilead Sciences Inc. Heart Failure Drugs Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Astra Zeneca Plc. Heart Failure Drugs Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Heart Failure Drugs Market Share by Manufacturer
Figure Global Heart Failure Drugs Revenue and Market Share by Manufacturer
Table Global Heart Failure Drugs Price by Region (2016-2017)
Figure Top 5 Heart Failure Drugs Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Heart Failure Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Heart Failure Drugs Market Forecast by Regions (2018-2025)
Figure North America Heart Failure Drugs Market Forecast (2018-2025)
Figure United States Heart Failure Drugs Market Forecast (2018-2025)
Figure Canada Heart Failure Drugs Market Forecast (2018-2025)
Figure Mexico Heart Failure Drugs Market Forecast (2018-2025)
Figure Europe Heart Failure Drugs Market Forecast (2018-2025)
Figure Germany Heart Failure Drugs Market Forecast (2018-2025)
Figure France Heart Failure Drugs Market Forecast (2018-2025)
Figure UK Heart Failure Drugs Market Forecast (2018-2025)
Figure Russia Heart Failure Drugs Market Forecast (2018-2025)
Figure Italy Heart Failure Drugs Market Forecast (2018-2025)
Figure Rest of Europe Heart Failure Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Heart Failure Drugs Market Forecast (2018-2025)
Figure China Heart Failure Drugs Market Forecast (2018-2025)
Figure Japan Heart Failure Drugs Market Forecast (2018-2025)
Figure Korea Heart Failure Drugs Market Forecast (2018-2025)
Figure India Heart Failure Drugs Market Forecast (2018-2025)
Figure Southeast Asia Heart Failure Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Heart Failure Drugs Market Forecast (2018-2025)
Figure South America Heart Failure Drugs Market Forecast (2018-2025)
Figure Brazil Heart Failure Drugs Market Forecast (2018-2025)
Figure Argentina Heart Failure Drugs Market Forecast (2018-2025)
Figure Columbia Heart Failure Drugs Market Forecast (2018-2025)
Figure Rest of South America Heart Failure Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Heart Failure Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Heart Failure Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Heart Failure Drugs Market Forecast (2018-2025)
Figure Egypt Heart Failure Drugs Market Forecast (2018-2025)
Figure Nigeria Heart Failure Drugs Market Forecast (2018-2025)
Figure South Africa Heart Failure Drugs Market Forecast (2018-2025)
Figure Turkey Heart Failure Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Heart Failure Drugs Market Forecast (2018-2025)
Figure Global Heart Failure Drugs Forecast by Drug Type (2018-2025)
Figure Global Heart Failure Drugs Market Share Forecast by Drug Type (2018-2025)
Figure Global Heart Failure Drugs Forecast by Drug Type (2018-2025)
Figure Global Heart Failure Drugs Forecast by Distribution Channel (2018-2025)
Figure Global Heart Failure Drugs Market Share Forecast by Distribution Channel (2018-2025)
Figure Global Heart Failure Drugs Forecast by Distribution Channel (2018-2025)

Please Note: Data related to the Companies are subject to Availability.


Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*